Chemistry:Redafamdastat

From HandWiki

Redafamdastat (INN; developmental code names JZP-150, PF-04457845) is an inhibitor of the enzyme fatty acid amide hydrolase (FAAH), with an IC50 of 7.2 nM, and both analgesic and anti-inflammatory effects in animal studies comparable to those of the cyclooxygenase inhibitor naproxen.[1] It was being developed by Jazz Pharmaceuticals for the treatment of alcoholism, pain, and post-traumatic stress disorder (PTSD) and reached phase 2 clinical trials.[2][3] However, development of the drug was discontinued in December 2023.[2]

See also

References

  1. ↑ "Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor". ACS Medicinal Chemistry Letters 2 (2): 91–96. February 2011. doi:10.1021/ml100190t. PMID 21666860. 
  2. ↑ 2.0 2.1 "JZP 150". 26 December 2023. https://adisinsight.springer.com/drugs/800029032. 
  3. ↑ A Study of JZP150 in Adults With Posttraumatic Stress Disorder - Full Text View - ClinicalTrials.gov. 5 December 2024. https://clinicaltrials.gov/ct2/show/NCT05178316. 




Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Redafamdastat&oldid=4031508"